Bench to Bedside
The ESC Bench to Bedside webinar series spotlights late-breaking clinical trials and examines the evidence set to revolutionise clinical practice and shape future guidelines.
A programme designed for you
An essential resource for every cardiology professional, from trainees seeking to better understand the clinical impact of trial results to general cardiologists and subspecialists aiming to stay up to date with both foundational knowledge and emerging evidence relevant to daily practice.
Enhancing clinical knowledge and practice
Each ESC Bench to Bedside issue offers an in-depth exploration of the basic science behind new therapies, insights into trial design and key data points, and expert evaluation of how novel treatments are likely to impact clinical practice.
ESC Bench to Bedside issues also provide a curated selection of relevant content, including trial publications, congress presentations, educational materials and more.
Expert-led webinars that inform, engage and inspire
From Science to Trials
Unpacks the science behind the new therapy, technology, or device.
From Trials to Results
In-depth look at trial design, key eligibility criteria, endpoints, and outcomes.
From Results to Patient Care
Evaluates the clinical implications of trial findings and the potential to improve outcomes.
Thank you to our volunteers for their expertise
"Bench to Bedside is a one-stop resource for cardiologists and allied professionals on the latest innovations that are relevant to their area of specialty."
Professor Theresa McDonagh
Chair of the ESC Education Committee and Bench to Bedside Programme
"Whether you’re a practicing cardiologist or trainee looking to reinforce your core knowledge, or a specialist wanting to stay updated on key developments across cardiology, this series is designed for you."
Professor Rudolf De Boer
Bench to Bedside Programme Co-Chair and ambassador for Basic Science
Issues
Bench to Bedside: Non-steroidal MRAs and Heart Failure
This edition provides a structured journey from foundational science through clinical trial evidence to practical applications of the evolving role of non-steroidal mineralocorticoid receptor antagonists (MRAs) in heart failure management.
Bench to Bedside: GLP-1 RAs and HFpEF
Focusing on recent advances, this issue highlights the emerging role of GLP-1 receptor agonists (GLP-1 RAs) and GIP agonists in the management of heart failure with preserved ejection fraction (HFpEF).